Abstract 3363: Resistin promotes tumor angiogenesis and lymphangiogenesis through c-Src/PI3K/AKT signaling pathway in human chondrosarcoma cells

Abstract

Abstract Chondrosarcoma is a kind of commonly found bone malignant tumor. The development of distant metastasis often leads to a significant decline in overall survival, and there are no specific therapeutic methods for it until today. For tumors to metastasize, angiogenesis and lymphangiogenesis are both important steps in the early periods. Resistin was discovered as an adipocyte-secreting adipokine, which may play a critical role in modulating cancer pathogenesis. However, the role of resistin in the angiogenesis and lymphangiogenesis of human chondrosarcoma is largely unknown. In our lab, we found that the expression of resistin was higher in chondrosarcoma biopsy tissues than in normal cartilage. We also confirmed that treated cells with resistin increased VEGFA and VEGFC expression, promoting angiogenesis as well as lymphangiogenesis in human chondrosarcoma cells. Moreover, the inhibitors and siRNAs of c-Src, PI3K, and AKT reduced the resistin-increased cell angiogenesis and lymphangiogenesis. Our results indicate that resistin promotes chondrosarcoma angiogenesis and lymphangiogenesis by the increasing VEGFA and VEGFC expression through the activation of the c-Src/PI3K/AKT signaling pathway expression. Therefore, resistin may represent a potential novel molecular therapeutic target for chondrosarcoma therapeutic treatment. Citation Format: Meng-Ju Chi, Hsiao-Chi Tsai, Chih-Hsin Tang. Resistin promotes tumor angiogenesis and lymphangiogenesis through c-Src/PI3K/AKT signaling pathway in human chondrosarcoma cells. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3363.